Healthcare · Profile from Healthcare Research Companion
GE HealthCare Technologies Inc.
The medical imaging and patient monitoring business that spent more than a century inside General Electric before becoming an independent company in January 2023. GE HealthCare is one of the "big three" global imaging makers alongside Siemens Healthineers and Philips. It sells CT, MRI, X-ray, molecular imaging and ultrasound systems, patient monitors and anesthesia machines, and the contrast agents and radiopharmaceuticals injected into patients for scans. Its history mirrors GE's: a pioneer in X-ray and CT, an acquirer (Amersham, Instrumentarium), a laboratory for Jeff Immelt's "reverse innovation," a cash source sold off in pieces during GE's 2018–2021 crisis, and finally a spin-off that has to prove it can grow on its own in a world of tariffs, Chinese competition and AI-assisted imaging.
At a glance
- Founded
- Roots in the Victor X-Ray Corporation (Chicago), acquired by GE in the 1920s (GE X-Ray Corporation from 1930); later GE Medical Systems; renamed GE Healthcare after the 2004 Amersham deal; independent company from 3–4 January 2023
- Founders
- Victor Electric/Victor X-Ray (founded in Chicago in the 1890s; founder names in older histories not re-checked here)
- Headquarters
- Chicago, Illinois
- Ownership / structure
- Public company, Nasdaq: GEHC (when-issued trading late 2022; regular trading from 4 January 2023). GE kept 19.9% at spin and sold it in stages from 2023 through debt-for-equity exchanges and secondary offerings; the last ~13.3m shares were sold in November 2024, completing GE's exit
- Leadership (2026)
- Peter J. Arduini, President and CEO (CEO of GE Healthcare since January 2022); Jay Saccaro, CFO; Neal Sandy becomes CEO of Patient Care Solutions from 16 November 2026 (replacing Jeannette Bankes)
- Segments
- Through Q1 2026: Imaging; Advanced Visualization Solutions (AVS: ultrasound, image-guided therapy); Patient Care Solutions (PCS: monitoring, anesthesia, maternal-infant care); Pharmaceutical Diagnostics (PDx). From Q2 2026 Imaging and AVS are combined as Advanced Imaging Solutions (AIS), giving three segments: AIS, PDx, PCS
- Payer and customer
- Hospitals, imaging centers and health systems buy equipment and service; PDx agents are bought by hospitals and pharmacies; scans are paid by Medicare (technical and professional components), commercial plans and national health systems
- Scale
- 2025 revenue ~$20.6bn (+4.8% reported, +3.5% organic); adjusted EBIT margin 15.3%; adjusted EPS $4.59; free cash flow ~$1.5bn; tariff cost ~$245m and China revenue −4.6% (reported). Q3 2026 revenue ~$5.5bn (+7.2%, +6.2% organic); 2026 guidance raised in October to ~4% organic growth and adjusted EPS $4.95–5.05. ~53,000–54,000 employees (end-2024 / end-2025, reported)
- Capital / market cap
- At the spin GEHC issued $8.25bn of senior notes (November 2022) plus a $2bn term loan, using most of the proceeds for distributions to GE; total debt ~$10.0bn at Q3 2026; investment-grade; market cap roughly $30–40bn in 2023–26 (approximate)
- Signature moves (incl. failures)
- Thomson CGR asset swap (1987); Amersham (2004); reverse innovation and healthymagination (2009); GE's 2018 spin plan and its reversal; biopharma sale to Danaher (2019–20); spin-off (2023); Flyrcado PET agent approval (2024); Intelerad deal and tariff shock (2025–26)
8 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
1987
Thomson CGR Asset Swap
Acquisition by asset swap
2004
Amersham Acquisition
Acquisition
2009
Reverse Innovation and Healthymagination
Product strategy / emerging-markets launch
2018
Spin Plan and Reversal
Spin-off (announced, then abandoned)
2019
Biopharma Sale to Danaher
Divestiture
2023
Spin Off from GE
Spin-off
2024
Flyrcado PET Agent Approval
Launch (new diagnostic drug)
2025
Intelerad Deal and Tariff Shock
Acquisition (software) and response to an external shock (tariffs, China)